Tyra Biosciences Inc (TYRA)

$9.63 -0.11 (-1.13%)
Market Cap 517.10M
Revenue (ttm) 0.00
Net Income (ttm) -86.48M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 111,800
Avg Vol 313,446
Day's Range N/A - N/A
Shares Out 53.09M
Stochastic %K 38%
Beta 1.07
Analysts Strong Sell
Price Target $30.14

Company Profile

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in clinical trials for the treatment of patients with...

Industry: Biotechnology
Sector: Healthcare
Phone: 619-728-4760
Website: tyra.bio
Address:
2656 State Street, Carlsbad, United States
MGeronimo
MGeronimo Jun. 20 at 10:14 PM
$TYRA 7.38 to 9.60 bam
0 · Reply
john565
john565 Jun. 18 at 1:58 PM
$TYRA The size and the timing of recent director sale is concerning
0 · Reply
rangerhawkeye
rangerhawkeye Jun. 17 at 8:56 PM
$CDXS added this and $TYRA , big insider buys by both
0 · Reply
MGeronimo
MGeronimo Jun. 17 at 3:07 PM
$TYRA IN at $10.12on 170k insider buying
0 · Reply
john565
john565 Jun. 16 at 1:29 PM
$TYRA how come average price target is 30 🤔..
0 · Reply
BennyBoy18
BennyBoy18 Jun. 12 at 6:13 PM
$TYRA inside buy , bullish?
0 · Reply
MoneyMediary
MoneyMediary Jun. 12 at 2:05 AM
$TYRA RA Capital just doubled down on TYRA with another $1.9M buy. That’s on top of $11.7M last week. Biotech is bleeding red, but this hedge fund is going all-in while others panic. This is how quiet money makes loud returns. https://moneymediary.com/p/billionaire-loads-up-on-biotech-again-5db9
0 · Reply
PivotPoint_101
PivotPoint_101 Jun. 9 at 3:11 AM
$TYRA
1 · Reply
rangerhawkeye
rangerhawkeye Jun. 8 at 4:04 PM
$TYRA big insider buy for almost 12 million, on watch, also $AQST on dips
0 · Reply
stockanalysis_
stockanalysis_ Jun. 7 at 4:34 AM
Today's After Hours Gainers Include: $OMH $TPST $TYRA $NCL $MB Check out the rest of the list here: https://stockanalysis.com/markets/afterhours/?ref=saveontrading
0 · Reply
Latest News on TYRA
Tyra Biosciences to Participate at Upcoming Investor Conferences

May 12, 2025, 4:05 PM EDT - 6 weeks ago

Tyra Biosciences to Participate at Upcoming Investor Conferences

Tyra Biosciences Reports First Quarter 2025 Financial Results and Highlights

May 8, 2025, 4:05 PM EDT - 6 weeks ago

Tyra Biosciences Reports First Quarter 2025 Financial Results and Highlights

Tyra Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights

Mar 27, 2025, 4:05 PM EDT - 3 months ago

Tyra Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights

Tyra Biosciences to Present at Upcoming Investor Conferences

Feb 11, 2025, 4:05 PM EST - 4 months ago

Tyra Biosciences to Present at Upcoming Investor Conferences

Tyra Biosciences Announces Poster Presentations at 2025 ASCO Gastrointestinal Cancers Symposium

Jan 22, 2025, 8:00 AM EST - 5 months ago

Tyra Biosciences Announces Poster Presentations at 2025 ASCO Gastrointestinal Cancers Symposium

Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Non-Muscle Invasive Bladder Cancer (SURF302)

Jan 10, 2025, 8:00 AM EST - 5 months ago

Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Non-Muscle Invasive Bladder Cancer (SURF302)

Tyra Biosciences Reports Third Quarter 2024 Financial Results and Highlights

Nov 7, 2024, 4:05 PM EST - 8 months ago

Tyra Biosciences Reports Third Quarter 2024 Financial Results and Highlights

Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia (BEACH301)

Oct 28, 2024, 7:00 AM EDT - 8 months ago

Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia (BEACH301)

Why Is Cancer-Focused Tyra Biosciences Stock Falling On Friday?

Oct 25, 2024, 11:34 AM EDT - 8 months ago

Why Is Cancer-Focused Tyra Biosciences Stock Falling On Friday?

Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC)

Oct 24, 2024, 6:21 PM EDT - 8 months ago

Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC)

Tyra Biosciences to Host Conference Call on Interim Clinical Data of TYRA-300 from SURF301 Phase 1/2 Study on October 25, 2024, at 8am ET

Oct 23, 2024, 4:05 PM EDT - 8 months ago

Tyra Biosciences to Host Conference Call on Interim Clinical Data of TYRA-300 from SURF301 Phase 1/2 Study on October 25, 2024, at 8am ET

Tyra Biosciences: Upcoming FGFR3 Inhibitor Data Is A Major Inflection Point

Oct 21, 2024, 7:55 AM EDT - 8 months ago

Tyra Biosciences: Upcoming FGFR3 Inhibitor Data Is A Major Inflection Point

BofA Upgrades Tyra Biosciences As Investors Focus On Preclinical Data Amid High Benchmarks Set By Johnson & Johnson's Drug

Oct 18, 2024, 2:34 PM EDT - 8 months ago

BofA Upgrades Tyra Biosciences As Investors Focus On Preclinical Data Amid High Benchmarks Set By Johnson & Johnson's Drug

This Datadog Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday

Oct 18, 2024, 9:51 AM EDT - 8 months ago

This Datadog Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday

DDOG ACI ECL VCTR

Tyra Biosciences Announces Late-Breaking Oral Presentation on Preliminary Safety and Anti-Tumor Activity of TYRA-300 from SURF301 at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2024)

Oct 11, 2024, 8:00 AM EDT - 9 months ago

Tyra Biosciences Announces Late-Breaking Oral Presentation on Preliminary Safety and Anti-Tumor Activity of TYRA-300 from SURF301 at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2024)

The Schall Law Firm Is Looking Into Tyra Biosciences Inc For Possibly Violating Securities Laws And The Firm Seeks Shareholder Participation

Sep 12, 2024, 11:00 AM EDT - 10 months ago

The Schall Law Firm Is Looking Into Tyra Biosciences Inc For Possibly Violating Securities Laws And The Firm Seeks Shareholder Participation

Tyra Biosciences to Present at the 2024 Cantor Global Healthcare Conference

Sep 11, 2024, 4:05 PM EDT - 10 months ago

Tyra Biosciences to Present at the 2024 Cantor Global Healthcare Conference

Tyra Biosciences, Inc. May Have Defrauded Shareholders And Impacted Individuals Are Invited To Join The Schall Law Firm's Investigation

Sep 11, 2024, 4:00 AM EDT - 10 months ago

Tyra Biosciences, Inc. May Have Defrauded Shareholders And Impacted Individuals Are Invited To Join The Schall Law Firm's Investigation

Tyra Biosciences Appoints Doug Warner, M.D., as Chief Medical Officer

Sep 10, 2024, 4:05 PM EDT - 10 months ago

Tyra Biosciences Appoints Doug Warner, M.D., as Chief Medical Officer

Tyra Biosciences, Inc. Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Wants Shareholders To Participate

Sep 9, 2024, 11:00 AM EDT - 10 months ago

Tyra Biosciences, Inc. Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Wants Shareholders To Participate

Fraudulent Practices May Have Been Committed By Tyra Biosciences Inc And Affected Investors Are Urged To Reach Out To The Schall Law Firm

Sep 7, 2024, 11:00 AM EDT - 10 months ago

Fraudulent Practices May Have Been Committed By Tyra Biosciences Inc And Affected Investors Are Urged To Reach Out To The Schall Law Firm

Investors Are Invited By The Schall Law Firm To Partake In An Inquiry In Tyra Biosciences, Inc's Possible Violations Of Securities Regulations

Sep 6, 2024, 11:00 AM EDT - 10 months ago

Investors Are Invited By The Schall Law Firm To Partake In An Inquiry In Tyra Biosciences, Inc's Possible Violations Of Securities Regulations

Tyra Biosciences, Inc. Is Being Looked Into For Acting Wrongfully And The Schall Law Firm Has Launched An Investigation That Shareholders Can Join

Sep 5, 2024, 11:00 AM EDT - 10 months ago

Tyra Biosciences, Inc. Is Being Looked Into For Acting Wrongfully And The Schall Law Firm Has Launched An Investigation That Shareholders Can Join

The Schall Law Firm Is Looking Into Tyra Biosciences Inc. For Possible Securities Related Infractions And Stockholders Can Assist

Sep 4, 2024, 11:00 AM EDT - 10 months ago

The Schall Law Firm Is Looking Into Tyra Biosciences Inc. For Possible Securities Related Infractions And Stockholders Can Assist

Tyra Biosciences Inc Stockholders Can Partake In An Inquiry Into Whether The Company Defrauded The Public

Sep 2, 2024, 11:00 AM EDT - 10 months ago

Tyra Biosciences Inc Stockholders Can Partake In An Inquiry Into Whether The Company Defrauded The Public

Attention Investors: The Schall Law Firm Is Looking Into Tyra Biosciences Inc. For Potentially Violating Securities Laws And Investors Can Reach Out

Sep 1, 2024, 11:00 AM EDT - 10 months ago

Attention Investors: The Schall Law Firm Is Looking Into Tyra Biosciences Inc. For Potentially Violating Securities Laws And Investors Can Reach Out

An Inquiry Is Being Made Into Whether Tyra Biosciences Has Defrauded The Public And The Schall Law Firm Wants Shareholders To Help

Aug 31, 2024, 11:00 AM EDT - 10 months ago

An Inquiry Is Being Made Into Whether Tyra Biosciences Has Defrauded The Public And The Schall Law Firm Wants Shareholders To Help

Tyra Biosciences May Have Broken Securities Laws And Impacted Stakeholders Are Urged To Lend A Hand To The Schall Law Firm's Inquiry

Aug 30, 2024, 11:00 AM EDT - 10 months ago

Tyra Biosciences May Have Broken Securities Laws And Impacted Stakeholders Are Urged To Lend A Hand To The Schall Law Firm's Inquiry

The Public Is Encouraged To Reach Out To The Schall Law Firm About An Inquiry Into Tyra Biosciences Inc.'s Potentially Fraudulent Actions

Aug 29, 2024, 11:00 AM EDT - 10 months ago

The Public Is Encouraged To Reach Out To The Schall Law Firm About An Inquiry Into Tyra Biosciences Inc.'s Potentially Fraudulent Actions

The Schall Law Firm Invites Investors In Tyra Biosciences Inc To Partake In An Investigation Into Securities Fraud

Aug 28, 2024, 11:00 AM EDT - 10 months ago

The Schall Law Firm Invites Investors In Tyra Biosciences Inc To Partake In An Investigation Into Securities Fraud

An Inquiry Has Been Opened Into Tyra Biosciences Inc's Possible Securities Related Impropriety And Impacted Stakeholders Should Join

Aug 27, 2024, 11:00 AM EDT - 10 months ago

An Inquiry Has Been Opened Into Tyra Biosciences Inc's Possible Securities Related Impropriety And Impacted Stakeholders Should Join

The Schall Law Firm Is Inquiring Into Tyra Biosciences Inc.'s Potential Securities Fraud And Affected Investors Can Participate

Aug 25, 2024, 11:00 AM EDT - 10 months ago

The Schall Law Firm Is Inquiring Into Tyra Biosciences Inc.'s Potential Securities Fraud And Affected Investors Can Participate

Tyra Biosciences Inc. Shareholders Can Reach Out To The Schall Law Firm About An Investigation Into Possible Breaches Of Securities Laws

Aug 24, 2024, 11:00 AM EDT - 10 months ago

Tyra Biosciences Inc. Shareholders Can Reach Out To The Schall Law Firm About An Investigation Into Possible Breaches Of Securities Laws

Investors With Losses In Tyra Biosciences Inc. Are Urged To Join An Inquiry Into Possible Securities Fraud With The Schall Law Firm

Aug 23, 2024, 11:00 AM EDT - 10 months ago

Investors With Losses In Tyra Biosciences Inc. Are Urged To Join An Inquiry Into Possible Securities Fraud With The Schall Law Firm

Tyra Biosciences Inc. Shareholders Encouraged To Participate In Securities Fraud Investigation With The Schall Law Firm

Aug 21, 2024, 10:15 PM EDT - 11 months ago

Tyra Biosciences Inc. Shareholders Encouraged To Participate In Securities Fraud Investigation With The Schall Law Firm

The Schall Law Firm Invites TYRA Stakeholders To Be A Part Of A Securities Fraud Investigation Into Tyra Biosciences, Inc.

Aug 21, 2024, 4:30 PM EDT - 11 months ago

The Schall Law Firm Invites TYRA Stakeholders To Be A Part Of A Securities Fraud Investigation Into Tyra Biosciences, Inc.

TYRA Investors Have Opportunity to Join Tyra Biosciences, Inc. Securities Fraud Investigation with the Schall Law Firm

Aug 20, 2024, 8:37 PM EDT - 11 months ago

TYRA Investors Have Opportunity to Join Tyra Biosciences, Inc. Securities Fraud Investigation with the Schall Law Firm

MGeronimo
MGeronimo Jun. 20 at 10:14 PM
$TYRA 7.38 to 9.60 bam
0 · Reply
john565
john565 Jun. 18 at 1:58 PM
$TYRA The size and the timing of recent director sale is concerning
0 · Reply
rangerhawkeye
rangerhawkeye Jun. 17 at 8:56 PM
$CDXS added this and $TYRA , big insider buys by both
0 · Reply
MGeronimo
MGeronimo Jun. 17 at 3:07 PM
$TYRA IN at $10.12on 170k insider buying
0 · Reply
john565
john565 Jun. 16 at 1:29 PM
$TYRA how come average price target is 30 🤔..
0 · Reply
BennyBoy18
BennyBoy18 Jun. 12 at 6:13 PM
$TYRA inside buy , bullish?
0 · Reply
MoneyMediary
MoneyMediary Jun. 12 at 2:05 AM
$TYRA RA Capital just doubled down on TYRA with another $1.9M buy. That’s on top of $11.7M last week. Biotech is bleeding red, but this hedge fund is going all-in while others panic. This is how quiet money makes loud returns. https://moneymediary.com/p/billionaire-loads-up-on-biotech-again-5db9
0 · Reply
PivotPoint_101
PivotPoint_101 Jun. 9 at 3:11 AM
$TYRA
1 · Reply
rangerhawkeye
rangerhawkeye Jun. 8 at 4:04 PM
$TYRA big insider buy for almost 12 million, on watch, also $AQST on dips
0 · Reply
stockanalysis_
stockanalysis_ Jun. 7 at 4:34 AM
Today's After Hours Gainers Include: $OMH $TPST $TYRA $NCL $MB Check out the rest of the list here: https://stockanalysis.com/markets/afterhours/?ref=saveontrading
0 · Reply
casedoog
casedoog Jun. 6 at 11:26 PM
$TYRA $EYEN $KNW $DTCK $FAAS Nice insider buy today. Nice chart, at breakout level worth a look
1 · Reply
FinJay
FinJay Jun. 6 at 2:10 AM
$TYRA https://youtu.be/b_jHQWo3tWk
0 · Reply
WAYWARD_SUN
WAYWARD_SUN Jun. 4 at 4:33 PM
$TYRA
0 · Reply
FinJay
FinJay May. 30 at 7:47 PM
$TYRA https://youtu.be/b_jHQWo3tWk
0 · Reply
Armonica423
Armonica423 May. 7 at 2:03 AM
$TYRA CYDY
0 · Reply
FinJay
FinJay Apr. 12 at 4:26 AM
$TYRA https://youtu.be/nwfvBvFhr_o
0 · Reply
JarvisFlow
JarvisFlow Mar. 31 at 11:30 AM
HC Wainwright & Co. has adjusted their stance on Tyra Biosciences ( $TYRA ), setting the rating to Buy with a target price of 30.
0 · Reply
JarvisFlow
JarvisFlow Mar. 28 at 1:48 PM
Wedbush updates rating for Tyra Biosciences ( $TYRA ) to Outperform, target set at 37.
0 · Reply
d_risk
d_risk Mar. 28 at 3:04 AM
$TYRA - Tyra Biosciences Inc. Common Stock - 10K - Updated Risk Factors TYRA's 2025 10-K Risk Factors highlight early-stage development challenges, with three clinical candidates and no approved products, emphasizing financial needs, regulatory hurdles, and IP risks. New risks include potential trial data rejection outside the U.S., FDA disruptions, and increased litigation threats. #Biotechnology #IntellectualProperty #FinancialChallenges #ClinicalTrials #RegulatoryRisks 🟢 Added 🟠 Removed https://d-risk.ai/TYRA/10-K/2025-03-27
0 · Reply
DonCorleone77
DonCorleone77 Mar. 27 at 9:14 PM
$TYRA Tyra Biosciences reports Q4 EPS (43c) vs. (53c) last year "2024 was a momentous year for TYRA and the patient communities we serve, highlighted by the positive interim results from our SURF301 study, which demonstrated a combination of high anti-tumor activity with favorable tolerability results in very sick, heavily pre-treated cancer patients. Importantly, the oncology doses tested in SURF301 are significantly higher than those to be tested in BEACH301, giving us confidence as we advance TYRA-300 in ACH," said Todd Harris, CEO of TYRA. "Our conviction in TYRA-300 has never been stronger and we are working diligently to advance this potential best-in-class agent for multiple high-value indications in oncology and skeletal dysplasia into three Phase 2 studies in NMIBC, ACH and mUC."
0 · Reply
FinJay
FinJay Mar. 26 at 4:11 AM
$TYRA https://youtu.be/nwfvBvFhr_o?si=OpgAi5PtbKpEsvow
0 · Reply
NVDAMillionaire
NVDAMillionaire Mar. 22 at 1:29 AM
$TYRA Digging TYRA's precision medicine approach. SURF301 interim data looks promising - 54.5% partial response in mUC. FGFR3 inhibitor could be game changer. Watching closely for Phase 2 NMIBC trial. Potential multi-bagger if clinical success continues. good article: https://beyondspx.com/article/tyra-biosciences-pioneering-next-generation-precision-medicines
0 · Reply